Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues

被引:40
作者
Bando, H
Brokelmann, M
Toi, M
Alitalo, K
Sleeman, JP
Sipos, B
Gröne, HJ
Weich, HA
机构
[1] GBF, Dept RDIF, D-38124 Braunschweig, Germany
[2] Tokyo Metropolitan Komagome Hosp, Tokyo, Japan
[3] Univ Helsinki, Canc Biol Lab, FIN-00014 Helsinki, Finland
[4] Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany
[5] German Canc Res Ctr, Dept Cellular & Mol Pathol, Heidelberg, Germany
关键词
VEGFR-3; sandwich-ELISA; lymphangiogenesis; growth factors;
D O I
10.1002/ijc.20211
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor recpetor-3 (VEGFR-3) and its ligands, vascular endothelial growth factor-C (VEGF-C) and -D (VEGF-D), are the major molecules involved in developmental and pathological lymphangiogenesis. Here we describe for the first time the development of a specific indirect enzyme-linked immunosorbent assay (ELISA) for the quantification of VEGFR-3 in different human cell and tissue lysates. A combination of the goat polyclonal anti-VEGFR-3 antibody and the mouse monoclonal anti-human VEGFR-3 antibody was used. The assay was highly sensitive and reproducible with a detection range of 0.2-25 ng/ml. The assay was specific for VEGFR-3, with no cross-reactivity to VEGFR-1 or VEGFR-2. Complex formation with VEGF-C and VEGF-D had no effect on the sensitivity of the assay. The VEGFR-3 concentration in the lysates of cultured human dermal microvascular endothelial cells was 14-fold higher than in the lysates from human umbilical vein endothelial cells. In human kidney, breast, colon, gastric and lung cancer tissues the protein levels of VEGFR-3 were in the range of 0.6-16.7 ng/mg protein. Importantly, the level of VEGFR-3 protein detected in the ELISA correlated significantly with the number of VEGFR-3 positive vessels observed in histochemical sections, suggesting that the ELISA assay may be a reliable surrogate of measuring VEGFR-3-positive vessel density. The protein levels of VEGFR-3 in 27 renal cell carcinoma samples had a significant correlation with the levels of VEGF-C (p<0.001), or biological active, free VEGF-A (p<0.0001), but not with VEGFR-1 or total VEGF-A. This assay provides a useful tool for the investigations of the expression levels of VEGFR-3 in physiological and pathological processes, particular in cancer and in lymphangiogenesis-related disease. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:184 / 191
页数:8
相关论文
共 49 条
[1]  
[Anonymous], 1988, Antibodies: A Laboratory Manual
[2]   Clinical significance of vascular, endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma [J].
Arinaga, M ;
Noguchi, T ;
Takeno, S ;
Chujo, M ;
Miura, T ;
Uchida, Y .
CANCER, 2003, 97 (02) :457-464
[3]  
BALDWIN ME, 2002, BIOASSAYS, V24
[4]  
BORG JP, 1995, ONCOGENE, V10, P973
[5]   The vascular endothelial growth factor receptor Flt-1 mediates biological activities - Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis [J].
Clauss, M ;
Weich, H ;
Breier, G ;
Knies, U ;
Rockl, W ;
Waltenberger, J ;
Risau, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (30) :17629-17634
[6]   Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy [J].
Dias, S ;
Choy, M ;
Alitalo, K ;
Rafii, S .
BLOOD, 2002, 99 (06) :2179-2184
[7]   Characterization of murine Flt4 ligand VEGF-C [J].
Fitz, LJ ;
Morris, JC ;
Towler, P ;
Long, A ;
Burgess, P ;
Greco, R ;
Wang, J ;
Gassaway, R ;
Nickbarg, E ;
Kovacic, S ;
Ciarletta, A ;
Giannotti, J ;
Finnerty, H ;
Zollner, R ;
Beier, DR ;
Leak, LV ;
Turner, KJ ;
Wood, CR .
ONCOGENE, 1997, 15 (05) :613-618
[8]  
FOURNIER E, 1995, ONCOGENE, V11, P921
[9]   CLINICAL IMPORTANCE OF THE DETERMINATION OF TUMOR ANGIOGENESIS IN BREAST-CARCINOMA - MUCH MORE THAN A NEW PROGNOSTIC TOOL [J].
GASPARINI, G ;
HARRIS, AL .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :765-782
[10]   Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling [J].
He, YL ;
Kozaki, KI ;
Karpanen, T ;
Koshikawa, K ;
Yla-Herttuala, S ;
Takahashi, T ;
Alitalo, K .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (11) :819-825